Investigators in the field of prostate cancer are always looking for ways to increase understanding about the disease, as well as improve diagnosis and treatment. Dr. Jeffrey Tomaszewski, an assistant professor at the Department of Surgery of the MD Anderson Cancer Center at Cooper Medical School of Rowan University is among them.
Dr. Tomaszewski was present at the 2016 American Urological Association Anual Meeting to present a new application of prostate cancer genomic tests. The physician is specialized in urological oncology, which includes prostate cancer and he discusses the use of common genomic biomarkers in different phases of prostate cancer screening, diagnosis, and treatment.
In this video, Dr. Tomaszewski explains that his research is focused on the use of either sample tissue or tissue from a resected prostate cancer to analyze the genetic mutation that caused the development of prostate cancer. Given the recent use of genomic biomarkers in the field, the physician advocates for the increase of information about it in order to improve prostate cancer diagnosis and treatment.
Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?